gl1 semaglutide Hims Inc Glucagon‐like peptide‐1 and semaglutide. (a)
Description
In chronic kidney disease, the pivotal FLOW trial demonstrated that semaglutide 1 mg reduced the risk of major kidney events by 24% in patients with type 2 diabetes and CKD, resulting in a dedicated indication in this population
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)work by mimicking the incretin hormone GLP-1
Semaglutide and tirzepatide do not activate the glucagon receptor
RECENT GUIDANCE ON THE USE OF GLP-1 RAs IN PATIENTS WITH T2D In consideration of recently reported cardiovascular and renal outcome data, multiple organizations have published updated guidance over the last several years regarding the use of glucose-lowering agents in patients with T2D to mitigate cardiovascular and renal risks
At $249.97 to $349.97 per month for ongoing treatment (after the first month), this represents a significant recurring expense
Below are eight companies worth considering, starting with the provider that stands out for accessibility, physician-guided care, and overall value
